Nanomix Corp. (NNMX)

[Paulness]

NEWS -- Nanomix to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

EMERYVILLE, Calif., March 22, 2022--(BUSINESS WIRE)--Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that David Ludvigson, President and Chief Executive Officer, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually March 28-30, 2022.

A pre-recorded company presentation will be available to conference attendees for 72 hours beginning March 28 at 9:00 a.m. Eastern time and can be accessed here. An archived replay of the webcast will also be available on Nanomix’s investor relations website. Interested investors may register for the conference to access the webcast at https://m-vest.com/events/2022-virtual-growth-conference.

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions and live Q&A with CEOs moderated by Maxim Research Analysts.

About Nanomix Corporation

Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nano.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005470/en/

Contacts

LHA Investor Relations
Tirth T. Patel
212-201-6614
mailto://[e-mail]